Catherine Woelfel

Title: **Catherine Woelfel: Pioneering Immunotherapy Innovations in Mainz, Germany**

Introduction

Catherine Woelfel is an innovative inventor based in Mainz, Germany. She has made significant contributions to the field of immunotherapy, focusing on tumor-associated antigens and their implications for cancer treatment. With two patents to her name, her work is poised to impact the medical landscape, particularly in targeting melanoma cells.

Latest Patents

Catherine Woelfel’s latest patents center around MHC-independent tumor-associated antigens. Her groundbreaking inventions relate to novel tumor-associated antigens that elicit a CD8-positive T-cell response independently of MHC presentation. Specifically, her research identified the GM-CSF receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) as targets for CD8-positive T-cell clones capable of detecting proteins on the surface of HLA I negative melanoma cells. These patents offer a range of medical applications, including treatments, diagnostics, and preventive measures for tumor diseases. Additionally, her inventions cover the development of proteins, protein fragments, and nucleic acids expressing these antigens, along with binding agents and T-cell receptors designed for specific reactivity.

Career Highlights

Catherine has built a commendable career through her association with leading organizations. She has worked for BioNTech RNA Pharmaceuticals GmbH, where she contributed to advancing cancer immunotherapies. Additionally, her tenure at Universitätsmedizin der Johannes Gutenberg-Universität Mainz further exemplifies her commitment to medical research and innovation.

Collaborations

Throughout her career, Catherine Woelfel has collaborated with notable professionals in her field. Among her coworkers are Dirk Schadendorf and Annette Paschen, both of whom are recognized for their expertise in cancer research and immunotherapy. This collaborative environment has greatly enriched her work and the impact of her inventions.

Conclusion

Catherine Woelfel continues to be a driving force in the realm of cancer treatment innovations. With her focus on MHC-independent tumor-associated antigens, her patents not only hold great promise for improving cancer therapies but also reflect her dedication to advancing medical science. Her efforts position her as a key figure in the ongoing battle against tumor diseases, making significant strides toward effective treatments.